title: Antithrombin replacement during extracorporeal membrane oxygenation.
abstract: Heparin remains the predominant anticoagulant during extracorporeal membrane oxygenation (ECMO). Heparin acts by potentiating the anticoagulant effect of antithrombin (ATIII). Acquired ATIII deficiency, common in pediatric patients requiring ECMO, may result in ineffective anticoagulation with heparin. ATIII replacement may result in increased bleeding. Our objective is to determine ATIII's effect on anticoagulation and blood loss during ECMO. A retrospective chart review was performed of all patients at Children's Hospital of Wisconsin who received ATIII while supported on ECMO in 2009. ATIII activity levels, heparin drip rate, and activated clotting times (ACT) were compared before, 4, 8, and 24 h after ATIII administration. Chest tube output and packed red blood cell (pRBC) transfusion volume were compared from 24 h before ATIII administration to 24 h after. Twenty-eight patients received ATIII as a bolus dose during the course of 31 separate times on ECMO support. The median age of these patients was 0.3 years (range 1 day-19.5 years). ATIII activity increased significantly at 8 and 24 h after administration. No significant difference was noted in heparin drip rate, ACT levels, chest tube output, or pRBC transfusion volume. ATIII administration resulted in higher ATIII activity levels for 24 h without a significant effect on heparin dose, ACT, or measures of bleeding.
authors.affiliation: Department of Pediatrics, Section of Critical Care, The Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI, USA. rniebler@mcw.edu
authors.forename: Robert A
authors.initials: RA
authors.lastname: Niebler
authors.forename: Melissa
authors.initials: M
authors.lastname: Christensen
authors.forename: Richard
authors.initials: R
authors.lastname: Berens
authors.forename: Heidi
authors.initials: H
authors.lastname: Wellner
authors.forename: Theresa
authors.initials: T
authors.lastname: Mikhailov
authors.forename: James S
authors.initials: JS
authors.lastname: Tweddell
mesh_terms: D000293:Adolescent; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000990:Antithrombin III / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D015199:Extracorporeal Membrane Oxygenation / Q000009:adverse effects*; D006470:Hemorrhage / Q000175:diagnosis / Q000209:etiology*; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D000990:Antithrombin III; D006493:Heparin